BMO Capital Markets downgraded MacroGenics Inc (NASDAQ:MGNX) to Market Perform following the discontinuation of enoblituzumab (B7H3 antibody) for head and neck cancers. The…
BMO Capital Market upgraded Fate Therapeutics Inc (NASDAQ:FATE) to Outperform from Market Perform. The analyst believes Fate’s iPSC platform is uniquely positioned…
Susquehanna analyst Christopher Stathoulopoulos downgrades JetBlue Airways (NASDAQ:JBLU) from Positive to Neutral and lowers the price target from $14 to $9.